Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Arcus Biosciences, Inc. RCUS

Healthcare  —  Biotechnology
24.97 (0.09) (0.36%) as of 25 Sep
Market cap
$3.2B
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Arcus Biosciences, Inc. (RCUS) Business Profile

Updated before January 2025

Company Overview

Arcus Biosciences, Inc. (NASDAQ: RCUS) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative cancer immunotherapies. Founded in 2015 and headquartered in Hayward, California, Arcus was established by a team of seasoned scientists and entrepreneurs with a mission to create transformative therapies for patients with cancer. The company was co-founded by Terry Rosen, Ph.D., who serves as the Chief Executive Officer, and Juan Jaen, Ph.D., who is the President and Head of Research and Development. Both leaders bring decades of experience in drug discovery and development, having held leadership roles at prominent pharmaceutical companies.

Arcus Biosciences operates with a collaborative and science-driven approach, leveraging its expertise in immuno-oncology to develop a robust pipeline of therapies. The company has established strategic partnerships with leading pharmaceutical companies, including Gilead Sciences, to accelerate the development and commercialization of its products.

Core Business Segments

Arcus Biosciences focuses on the development of cancer immunotherapies, with its core business segments centered around the following product categories:

Immuno-Oncology Therapies

  1. Domvanalimab (Anti-TIGIT Antibody): Domvanalimab is a monoclonal antibody targeting TIGIT, an immune checkpoint receptor. It is designed to enhance the immune system’s ability to detect and destroy cancer cells. Domvanalimab is currently in clinical trials for various cancers, including non-small cell lung cancer (NSCLC).

  2. Etrumadenant (A2a/A2b Adenosine Receptor Antagonist): This small molecule drug targets the adenosine pathway, which is often exploited by tumors to suppress immune responses. Etrumadenant is being evaluated in combination with other therapies for its potential to improve cancer treatment outcomes.

  3. Quemliclustat (Small Molecule CD73 Inhibitor): Quemliclustat inhibits CD73, an enzyme that plays a role in the production of adenosine. By blocking CD73, the therapy aims to enhance anti-tumor immune responses.

  4. AB308 (Anti-TIGIT Antibody): AB308 is a second anti-TIGIT antibody in Arcus’s pipeline, designed to complement domvanalimab and expand the company’s TIGIT-targeting portfolio.

Combination Therapies

Arcus is also focused on developing combination therapies that integrate its proprietary molecules with other immuno-oncology agents. These combinations aim to address the complex mechanisms of cancer and improve patient outcomes.

Strategic Collaborations

Through its partnership with Gilead Sciences, Arcus has access to significant resources and expertise to advance its pipeline. This collaboration includes co-development and co-commercialization agreements for several of Arcus’s key assets.

Business Model

Arcus Biosciences operates on a research-driven business model that integrates cutting-edge science with strategic partnerships. The company generates revenue primarily through milestone payments, licensing agreements, and potential royalties from its collaborations. By focusing on early-stage drug discovery and leveraging partnerships for late-stage development and commercialization, Arcus minimizes financial risk while maximizing its scientific impact.

The company invests heavily in research and development (R&D) to maintain a robust pipeline of innovative therapies. Its approach involves identifying novel targets, developing proprietary molecules, and conducting rigorous clinical trials to validate their efficacy and safety.

Strategic Direction

Arcus Biosciences is committed to advancing its pipeline of immuno-oncology therapies and expanding its presence in the biopharmaceutical market. Key strategic priorities include:

  1. Pipeline Expansion: Arcus aims to broaden its portfolio by exploring new therapeutic targets and developing next-generation immunotherapies.

  2. Global Reach: The company plans to expand its clinical trials to international markets, ensuring access to its therapies for patients worldwide.

  3. Sustainability Goals: Arcus is dedicated to sustainable practices in its operations, including reducing its environmental footprint and promoting diversity and inclusion within its workforce.

  4. Strategic Partnerships: The company continues to seek collaborations with leading pharmaceutical companies to accelerate the development and commercialization of its therapies.

Competitive Landscape

Arcus Biosciences operates in a highly competitive biopharmaceutical market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Merck & Co., Inc.: Known for its blockbuster immunotherapy Keytruda, Merck is a major player in the oncology space.
  • Bristol-Myers Squibb: The company offers a range of immuno-oncology therapies, including Opdivo and Yervoy.
  • Roche/Genentech: Roche is a leader in cancer immunotherapy, with products like Tecentriq and a strong pipeline of investigational drugs.
  • AstraZeneca: AstraZeneca’s portfolio includes Imfinzi and other innovative cancer treatments.
  • Smaller Biotech Firms: Companies like BeiGene and Iovance Biotherapeutics also compete in the immuno-oncology space, focusing on novel approaches to cancer treatment.

Risk Factors

Arcus Biosciences faces several risks that could impact its business operations and financial performance:

  1. Clinical Trial Risks: The success of Arcus’s therapies depends on the outcomes of clinical trials, which are inherently uncertain and time-consuming.

  2. Regulatory Challenges: The company must navigate complex regulatory pathways to obtain approval for its therapies.

  3. Market Dependence: Arcus relies heavily on its partnership with Gilead Sciences for funding and commercialization support.

  4. Supply Chain Disruptions: Any disruptions in the supply chain could delay the development and delivery of its therapies.

  5. Competitive Pressure: The biopharmaceutical market is highly competitive, with rapid advancements in technology and science.

Recent Developments

Arcus Biosciences has made significant progress in advancing its pipeline and strengthening its strategic position:

  • Clinical Trial Updates: The company recently announced positive interim results from its Phase 2 clinical trials for domvanalimab in combination with other therapies for NSCLC.
  • Partnership Milestones: Arcus achieved key milestones in its collaboration with Gilead Sciences, resulting in milestone payments and expanded co-development agreements.
  • New Research Initiatives: The company launched new preclinical programs targeting novel pathways in cancer immunotherapy.

Investment Considerations

Strengths

  • Robust Pipeline: Arcus has a diverse portfolio of innovative therapies targeting multiple cancer pathways.
  • Strategic Partnerships: The collaboration with Gilead Sciences provides financial stability and accelerates development timelines.
  • Experienced Leadership: The company’s leadership team has a proven track record in drug discovery and development.

Risks

  • High R&D Costs: The company invests heavily in R&D, which may impact short-term profitability.
  • Regulatory Uncertainty: Delays or failures in obtaining regulatory approvals could hinder growth.
  • Market Competition: Arcus faces intense competition from established players and emerging biotech firms.

Conclusion

Arcus Biosciences is well-positioned in the biopharmaceutical market, with a strong focus on cancer immunotherapy and a robust pipeline of innovative therapies. The company’s strategic partnerships and experienced leadership provide a solid foundation for future growth. While challenges such as regulatory hurdles and market competition remain, Arcus’s commitment to scientific innovation and patient-centric solutions makes it a promising player in the oncology space. Investors should weigh the company’s strengths and risks when considering it as a potential investment opportunity.